Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab.

@article{Glassy2009SummaryAO,
  title={Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab.},
  author={Mark C. Glassy and Hideaki Hagiwara},
  journal={Human antibodies},
  year={2009},
  volume={18 4},
  pages={127-37}
}
Pritumumab is a human IgG1 kappa antibody that has been derived from a B-cell isolated from a regional draining lymph node of a patient with cervical carcinoma. Specificity analysis of the antibody with human tissues showed the antigen, altered tumor-associated vimentin, to be highly restricted to various cancers and not normal cells and tissues. In various clinical trials in Japan 249 patients with brain cancer were treated with pritumumab. The overall response rate was between 25-30% with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

8th Annual European Antibody Congress 2012

mAbs • 2013
View 17 Excerpts
Highly Influenced

Role of the constant region domain in the structural diversity of human antibody light chains.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology • 2017

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Results of an immunotherapy using human monoclonal antibody for gliomas: findings in ten cases

T. Iwakoshi, T. Kobayashi, +4 authors R. Kitamura
Jpn J Neurosurg 5 • 1996
View 6 Excerpts
Highly Influenced

Clinical application of I-131 labeled human monoclonal antibody CLN-IgG on recurrent malignant glioma – preliminary report

M. Nagai, T. Arai, K. Watanabe, K. Ichikawa, T. Watari
Neuroimmunological Research 3 • 1990
View 4 Excerpts
Highly Influenced

[Anti-TA226 human monoclonal antibody (ACA-11) against glioma].

Nihon rinsho. Japanese journal of clinical medicine • 2002
View 5 Excerpts
Highly Influenced

Clinical late phase II study of human monoclonal antibody (ACA11) against human glioma

T. Kokunai, H. Tomita, S. Urui, N. Tamaki, S. Matsumoto
Neuroimmunological Res 12 • 1999
View 5 Excerpts
Highly Influenced

Clinical Phase 1 study of human monoclonal antibody

S. Matsumoto, T. Kokunai, +10 authors F. Ikuta
ACA-11 (CLN-IgG) against human malignant brain tumors, The Clinical Report 28 • 1994
View 4 Excerpts
Highly Influenced

K

S. Masumoto, M. Nagai, H. Takahashi, S. Nakazawa
Taka- M.C. Glassy and H. Hagiwara / Pre-clinical and clinical results of brain tumor patients treated with pritumumab 137 kuras, M. Matsutani, R. Tanaka, J. Yamashita, T. Kobayashi, Y. Oda, H. Kikuchi, T. Kokunai, N. Tamaki, K. Taomoto, H. Fukui, K. Tabuchi and Y. Ushio, Early Phase II study of hu • 1994
View 5 Excerpts
Highly Influenced

Antitumor effects of human monoclonal antibodies on human malignant glioma xenografts and their clinical application

K. Tawamoto, A. Ijichi, S. Matsumoto, H. Hagiwara
in: Biological Aspects of Brain Tumors, K. Tabuchi, ed., Springer- Verlag • 1991
View 4 Excerpts
Highly Influenced

Uc 729-6

M. C. Glassy, H. H. Handley, H. Hagiwara, I. Royston
a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas. Proc. Natl, Acad Sci 80 • 1983
View 5 Excerpts
Highly Influenced

Dougan and G . Dranoff , Immune therapy for cancer

J. M. Reichert
Ann Rev Immunol • 2009

Similar Papers

Loading similar papers…